What is a Half-life?
One of the most incorrectly used but most often quoted parameters is half life. The…
CertaraDecember 20, 2010
Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales
This article demonstrates techniques for describing and predicting disease progression in acute stroke by modeling…
CertaraDecember 1, 2010
Development of a Modeling Framework to Simulate Efficacy Endpoints for Motesanib in Thyroid Cancer Patients
To develop a modeling framework that simulates clinical endpoints (objective response rate and progression-free survival)…
CertaraNovember 1, 2010
Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients
To develop a population pharmacokinetic/pharmacodynamic model describing the relationship between motesanib exposure and tumor response…
CertaraNovember 1, 2010
A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551
Pharmacokinetic-pharmacodynamic relationships are crucial in understanding a drug's arrhythmogenic potential. Models assist to quantitatively relate…
CertaraAugust 21, 2010
Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis
In this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients…
CertaraJuly 1, 2010
What Does Clearance Mean?
Drug clearance is an extremely important topic in the science of pharmacokinetics. Drug clearance defines…
CertaraJune 13, 2010
Understanding Volume of Distribution
Register for our July 10 webinar and discover fast, flexible, frictionless PK/PD workflows with Phoenix…
CertaraJune 5, 2010
Pharmacology and Safety of Glycerol Phenylbutyrate in Healthy Adults and Adults with Cirrhosis
Phenylbutyric acid (PBA), which is approved for treatment of urea cycle disorders (UCDs) as sodium…
CertaraJune 1, 2010
